Validation of surrogate endpoint biomarkers in prostate cancer chemoprevention trials

Urology

Volumn 57, Issue 4 SUPPL. 1, 2001, Pages 241-247

  Trock, Bruce J ^a,b  

^a GEORGETOWN UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

APOPTOSIS; ARTICLE; BLOOD; CELL DIVISION; HUMAN; MALE; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PATHOPHYSIOLOGY; PHASE 2 CLINICAL TRIAL; PROSTATE TUMOR; PROSTATIC INTRAEPITHELIAL NEOPLASIA; REPRODUCIBILITY; RISK ASSESSMENT;

APOPTOSIS; CELL DIVISION; CLINICAL TRIALS, PHASE II; HUMANS; MALE; NEOVASCULARIZATION, PATHOLOGIC; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROSTATIC NEOPLASMS; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; TUMOR MARKERS, BIOLOGICAL;

EID: 0035319546     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0090-4295(00)00983-3     Document Type: Article

References (12)

1. Kelloff GJ, Johnson JR, Crowell JA, et al: Approaches to the development and marketing approval of drugs that prevent cancer. Cancer Epidemiol Biomarkers Prev 4: 1-10, 1995.
2. Schatzkin A, Freedman LS, Dorgan J, et al: Surrogate end points in cancer research: a critique. Cancer Epidemiol Biomarkers Prev 5: 947-953, 1996.
3. Bostwick DG, Burke HB, Wheeler TM, et al: The most promising surrogate endpoint biomarkers for screening candidate chemopreventive compounds for prostatic adenocarcinoma in short-term phase II clinical trials. J Cell Biochem Suppl 19: 283-289, 1994.
4. Redman C, Scott JA, Baines AT, et al: Inhibitory effect of selenomethionine on the growth of three selected human tumor cell lines. Cancer Lett 125: 103-110, 1998.
5. Bostwick DG: Prostatic intraepithelial neoplasia is a risk factor for cancer. Semin Urol Oncol 17: 187-198, 1999.
6. Schatzkin A, Freedman LS, Schiffman MH, et al: Validation of intermediate end points in cancer research. J Natl Cancer Inst 82: 1746-1752, 1990.
7. Adams JM, and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
8. Montironi R, Magi Galluzzi C, Diamanti L, et al: Prostatic intra-epithelial neoplasia: qualitative and quantitative analyses of the blood capillary architecture on thin tissue sections. Pathol Res Pract 189: 542-548, 1993.
9. Copeland KT, Checkoway H, McMichael AJ, et al: Bias due to misclassification in the estimation of relative risk. Am J Epidemiol 105: 488-495, 1977.
10. Urban D, Myers R, Manne U, et al: Evaluation of biomarker modulation by fenretinide in prostate cancer patients. Eur Urol 35: 429-438, 1999.
11. Wills ML, Hamper UM, Partin AW, et al: Incidence of high-grade prostatic intraepithelial neoplasia in sextant needle biopsy specimens. Urology 49: 367-373, 1997.
12. Presti JC Jr, Chang JJ, Bhargava V, et al: The optimal systematic prostate biopsy scheme should include 8 rather than 6 biopsies: results of a prospective clinical trial. J Urol 163: 163-166, 2000.